A Phase I Maximum Tolerated Dose Study of CI-1012 in Late-Stage HIV+ Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To determine the maximum tolerated dose of CI-1012 in late-stage HIV-1-infected patients. To
determine the antiretroviral activity of CI-1012 when added to combination therapy. To assess
the multiple-dose pharmacokinetic characteristics of CT-1012 when added to combination
therapy. To assess the effect of CI-1012 on the pharmacokinetics of other antiretroviral
agents.